# Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma

> **NCT05710198** · PHASE3 · RECRUITING · sponsor: **Omikron Italia S.r.l.** · enrollment: 1000 (estimated)

## Conditions studied

- Glaucoma, Open-Angle

## Interventions

- **DRUG:** Citicoline eye drops 2%
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05710198
- **Lead sponsor:** Omikron Italia S.r.l.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-11
- **Primary completion:** 2026-04-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05710198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05710198, "Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05710198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*